This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/5/2026
Please stand by, your meeting is about to begin. Hello and welcome everyone joining today's Arcturus Therapeutics third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star one on your telephone keypad. Please note, this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations and Marketing. Please go ahead.
Thank you, Operator. Good afternoon and welcome to Arcturus Therapeutics Quarterly Financial Update and Pipeline Progress Call. Today's call will be led by Joe Payne, our President and CEO, and Dennis Mulroy, our Chief Financial Officer. Dr. Pat Chivukula, our CSO and COO, and Dr. Alan Cohen, our Chief Medical Officer, will join them for the Q&A session. Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today. as well as the risk factors section in our most recent Form 10-K and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements. And with that, I will now turn the call over to Joe.
Thank you, Neda. Good afternoon, everyone, and thank you for joining us today. The third quarter was an important period for Arcturus as we continued to advance our key clinical programs, introduced our next generation Lunar 2.0 delivery platform, and expanded our pipeline of mRNA therapeutics. I'd like to begin with our liver therapeutics franchise, where we believe we are entering a new, exciting phase of development. In September, we presented encouraging phase two data from ARCT 810, in patients with ornithine transcarbamylase or OTC deficiency. At the 0.3 and 0.5 milligram per kilogram dose levels, ARCT 810 demonstrated meaningful biomarker activity, reducing and or maintaining first morning fasting ammonia within the normal range, including during increased protein intake and reducing glutamine levels in all participants with the 0.5 milligram per kilogram dose achieving mean glutamine concentrations within the normal range during treatment and was generally safe and well tolerated. These results provide important clinical validation of our mRNA approach to liver therapeutics and contributed to the development of our next generation OTC program called ARCT2601. ARCT2601 is particularly significant for Arcturus because it is the first mRNA therapeutic candidate utilizing our new Lunar 2.0 delivery technology. Non-human primate models have consistently demonstrated strong translational predictivity for lipid nanoparticle formulated RNA therapeutics. This is well documented. And in non-human primates, we can measure human ornithine transcarbamylase expression. And in this non-human primate model, We demonstrated a 38-fold improvement in potency using Lunar 2.0 compared to the original Lunar formulation that we used in ARC-TA10. We believe this substantial improvement in delivery efficiency has the potential to enable lower and less frequent dosing and potentially broaden the range of diseases we can address with our mRNA therapeutics. We shared the Lunar 2.0 data with the FDA. Following favorable FDA feedback and clarity on the regulatory pathway from our Type C meeting in June, we now plan to initiate Phase 2 dosing of ARCT 2601 next quarter. The amended protocol will evaluate patients with OTC deficiency, ages 12 and older, and we expect top-line data in the second half of 2027. Central to our thesis is safe and effective delivery of mRNA. We work in the field of RNA therapeutics where delivery is everything. So you can understand why we are looking forward to seeing this first potential clinical top line data for ARCT 2601, as this is the first opportunity to confirm how the 38-fold improvement we observed in non-human primates translates into patients. Beyond OTC deficiency, Lunar 2.0 is enabling us to expand our liver therapeutics pipeline and two additional genetic diseases including phenylketonuria or PKU and gout. For PKU, we are developing an investigational lunar 2.0 formulated mRNA therapy designed to enable the liver to produce functional PAH. This is the enzyme that is deficient in patients with PKU. Our objective is to restore PAH activity, improve phenylalanine metabolism and ultimately address the underlying cause of the disease. We currently plan to submit an IND for this program in the second half of 2027. Turning now to our respiratory franchise. We continue to make progress with ARCT 032 and CF. Enrolment in cohort four of the phase two study has accelerated as we have activated additional clinical sites in Israel and Turkey. We expect enrolment to be completed by year-end, with full cohort 4 data planned for presentation in the second quarter of 2027. Cohort 4 is evaluating 10 mg of ARCTO32 administered by inhalation for 12 weeks in up to 20 adults with cystic fibrosis, primarily Class 1 CF subjects. We are also pleased with the continued support of Thermo Fisher Scientific, for the ARCTO32 program. Under our collaboration, a decision to advance ARCTO32 into phase three would trigger significant contributions from Thermo Fisher with that decision expected when top line data is available before our planned phase two full data presentation. With the ongoing bolus of patients enrolling in Turkey and Israel, the data generated from these patients may be included to inform that decision. Thermo Fisher receives regular updates in accordance with our agreement, and per the agreement, the decision to advance ARCTO32 into Phase 3 remains under Arcturus' control. During the quarter, we also continued to strengthen our broader technology capabilities and AI infrastructure. We completed the acquisition of MyNeo, adding AI-driven capabilities in antigen design, On the vaccine side of our business, CoStave. Our self-amplifying mRNA COVID vaccine continues to be commercialized in Japan through our partner Meiji for the 2026-2027 season. We also successfully completed the transfer of the marketing authorization holder rights for COSTAVE in both the European Union and the United Kingdom from CSL Securus to Arcturus. These transfers are an important step as we move toward executing commercial objectives for COSTAVE in 2027. We also recently published the results of our phase one study for our self-amplifying mRNA pandemic influenza vaccine in Nature Communications. The study demonstrated immunological benefits compared with standard of care, a favorable safety profile, and the potential for a single dose pandemic response. Taken together, we believe these developments in our vaccine enterprise demonstrate the breadth of our mRNA platform and the evolution of Arcturus. We now have important programs progressing across respiratory and liver therapeutics, a next-generation delivery technology with Lunar 2.0, an expanding pipeline in genetic diseases, additional AI-enabled discovery capabilities through MyNeo, and a commercial vaccine platform led with CoStave. Looking ahead, we have several important milestones approaching. We expect to complete enrollment in the ARCT 032 Phase 2 study by year end, present the full Phase 2 CF data in the second quarter of 2027, initiate Phase 2 dosing of ARCT 2601 in the first quarter of 2027, and report top line ARCT 2601 data in the second half of 2027. Our focus remains on disciplined execution and advancing the programs where we believe our technology can deliver meaningful differentiation and patience and long-term value for shareholders. With that, I'll turn the call over to Dennis to review our third quarter financial results.
You're reading a preview of the ARCT Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing